<div id="readability-page-1"><div><p>Jinxin Fertility Group (SEHK:1951) has opened FY 2025 with first half revenue of C¥1.29b and a basic EPS loss of C¥0.39, setting a cautious tone around profitability despite solid scale. Over the past year, revenue has moved from C¥1.44b in the first half of 2024 to C¥1.29b in the first half of 2025, while EPS shifted from C¥0.07 and C¥0.03 in the 2024 halves to a trailing 12 month loss of about C¥0.36. This points to compressed margins that put the focus firmly on how quickly management can steady earnings.</p> <p>See our full analysis for Jinxin Fertility Group.</p><p>With the latest numbers on the table, the next step is to see how this earnings profile lines up with the widely followed growth and profitability narratives around Jinxin Fertility Group, and where those stories might be challenged by the data.</p> <p>Curious how numbers become stories that shape markets? Explore Community Narratives</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a8ac3603-4a10-4910-9aa9-86fc3b6cb970/chart/revenue-and-expenses-breakdown/query-ZGF0ZT0yMDI2LTAzLTI3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a8ac3603-4a10-4910-9aa9-86fc3b6cb970/chart/revenue-and-expenses-breakdown/query-ZGF0ZT0yMDI2LTAzLTI3"/><figcaption>SEHK:1951 Revenue &amp; Expenses Breakdown as at Mar 2026</figcaption></figure> <h2>TTM loss of C¥976m highlights profit pressure</h2> <ul> <li>On a trailing 12 month basis, Jinxin reports revenue of C¥2.65b and a net loss of C¥976m, compared with C¥2.81b revenue and C¥283m net income in the prior trailing window.</li> <li>Critics highlight that the bearish concern about weak profitability is heavily backed by the swing from C¥283m net income in the earlier trailing period to a C¥976m loss now.     <ul> <li>Basic EPS has moved from C¥0.11 on the 2024 trailing 12 month view to a loss of about C¥0.36. This lines up with the idea of worsening earnings.</li> <li>The first half of FY 2025 alone shows a C¥1.04b net loss versus C¥190m net income in the first half of 2024, so the latest half contributes strongly to the larger loss profile.</li> </ul> </li> </ul> <h2>2.1x P/S despite current losses</h2> <ul> <li>The shares trade on a P/S of 2.1x, above the Hong Kong healthcare industry at 1.0x and above peers at 1.7x, even though the company is loss making on a trailing 12 month basis.</li> <li>What stands out for a bearish narrative is that a premium P/S sits alongside five year losses that have grown at 52.4% per year.     <ul> <li>Over the last 12 months, the company has reported a trailing net loss of C¥976m, which contrasts with the higher multiple investors are currently paying.</li> <li>With the share price at HK$2.32 and revenue at C¥2.65b, bears argue that the valuation already reflects confidence in a turnaround that is not yet visible in the reported figures.</li> </ul> </li> </ul><p> On these numbers, skeptics who focus on the premium P/S ratio and the move to a C¥976m loss will want to stress test their thesis against a detailed breakdown of margins, cash generation, and capital allocation in the latest report before deciding how much risk they are comfortable taking on if the recovery takes longer than expected. <strong>🐻 Jinxin Fertility Group Bear Case</strong></p><h2>Forecast growth vs DCF fair value gap</h2> <ul> <li>Forecasts in the provided data point to revenue growth of 9.6% per year and earnings growth at a very large rate, while a DCF fair value of HK$6.92 sits well above the current HK$2.32 share price.</li> <li>Bullish investors argue that strong projected earnings growth supports the DCF fair value being higher than today's price.     <ul> <li>Modelled revenue growth of 9.6% per year compared with 8.2% for the wider Hong Kong market is one part of that argument, even though current trailing revenue is C¥2.65b with a loss.</li> <li>The gap between the HK$6.92 DCF fair value and the HK$2.32 market price is framed as potential upside by bulls, who see the current C¥976m trailing loss as a temporary phase ahead of the expected move back to profitability within three years.</li> </ul> </li> </ul> <h2>Next Steps</h2> <p>Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Jinxin Fertility Group's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.</p> <p>With sentiment in the article mixed, this is a good moment to look at the full data set yourself and decide where you stand. To understand why some investors view the company positively, you can examine its 2 key rewards more closely.</p> <h2>See What Else Is Out There</h2> <p>Jinxin Fertility Group is working through a C¥976m trailing loss, weaker margins, and a premium 2.1x P/S that investors may find hard to justify.</p> <p>If you want ideas where pricing looks more aligned with fundamentals right now, check out companies in the 234 high quality undervalued stocks and see how they compare on risk and reward.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><p>Try a Demo Portfolio for Free</p></div></div></div>

01951

<p>Jinxin Fertility Group (SEHK:1951) reported a first half FY 2025 revenue of C¥1.29b and a basic EPS loss of C¥0.39, indicating profitability concerns. The company experienced a significant decline in revenue and a net loss of C¥976m over the trailing 12 months. Despite trading at a premium P/S of 2.1x, critics question the valuation given the ongoing losses. While bullish investors see potential upside based on projected revenue growth and a DCF fair value of HK$6.92, skeptics urge caution due to the current financial performance.</p>

Jinxin Fertility Group FY 2025 Loss Spurs Debate On Premium Valuation Narratives